Publicaciones en colaboración con investigadores/as de Universidad de Extremadura (18)

2024

  1. Cómo estimar la composición corporal en la enfermedad de Huntington. Estudio transversal y observacional con bioimpedancia de múltiples frecuencias

    Revista de neurologia, Vol. 78, Núm. 1, pp. 17-25

  2. Validation of ActiGraph and Fitbit in the assessment of energy expenditure in Huntington's disease

    Gait and Posture, Vol. 109, pp. 89-94

2017

  1. Association between the rs1229984 polymorphism in the alcohol dehydrogenase 1B gene and risk for restless legs syndrome

    Sleep, Vol. 40, Núm. 12

  2. Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome

    Journal of Neural Transmission, Vol. 124, Núm. 3, pp. 285-291

2015

  1. Neuronal nitric oxide synthase (nNOS, NOS1) rs693534 and rs7977109 variants and risk for restless legs syndrome

    Journal of Neural Transmission, Vol. 122, Núm. 6, pp. 819-823

  2. A Parkinson's disease tele-education program for health care providers in Cameroon

    Journal of the Neurological Sciences, Vol. 357, Núm. 1-2, pp. 285-287

  3. Association between Vitamin D receptor rs731236 (Taq1) polymorphism and risk for restless legs syndrome in the Spanish caucasian population

    Medicine (United States), Vol. 94, Núm. 47, pp. e2125

  4. Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Restless Legs Syndrome

    Medicine (United States), Vol. 94, Núm. 34, pp. e1448

2014

  1. The solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene, SLC1A2, rs3794087 variant and assessment risk for restless legs syndrome

    Sleep Medicine, Vol. 15, Núm. 2, pp. 266-268

2013

  1. Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome

    Sleep Medicine

  2. Impact of placebo assignment in clinical trials of tic disorders

    Movement Disorders, Vol. 28, Núm. 9, pp. 1288-1292

  3. MAPT1 gene rs1052553 variant is unrelated with the risk for restless legs syndrome

    Journal of Neural Transmission, Vol. 120, Núm. 3, pp. 463-467

2012

  1. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease

    Movement Disorders, Vol. 27, Núm. 3, pp. 439-442

2010

  1. What contributes to driving ability in Parkinson's disease

    Disability and Rehabilitation, Vol. 32, Núm. 5, pp. 374-378

2009

  1. Impacto de los síntomas motores y no motores en los costes directos de la enfermedad de Parkinson

    Neurologia, Vol. 24, Núm. 1, pp. 15-23

2008

  1. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: An 18-week, single-center, dose-escalating, prospective, open-label study

    Clinical Therapeutics, Vol. 30, Núm. 1, pp. 182-189

2006

  1. Estudio de las variables clínicas asociadas y fenomenología de las alucinaciones en la enfermedad de Parkinson

    Neurologia, Vol. 21, Núm. 1, pp. 12-18

2002

  1. The importance of educational and psychological factors in Parkinson's disease quality of life

    European Journal of Neurology, Vol. 9, Núm. 6, pp. 589-593